Alligator Bioscience enters an exclusive collaboration agreement with Johnson & Johnson
12 August 2015
Alligator Bioscience, developing innovative antibody based immunotherapies for the treatment of cancer, has entered into a multi-million dollar agreement with Janssen Biotech, Inc.
Under the agreement, Janssen, will be granted an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013. Alligator Bioscience will receive an up-front payment plus additional contingent payments upon reaching certain pre-determined development, regulatory and commercial milestones up to a potential total of US$700 million.
"ADC-1013 is a great addition to our growing immuno-oncology portfolio, which includes a broad range of approaches, in both solid tumors and hematologic malignancies," said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen Research & Development, LLC. "We were very impressed with the properties of this antibody and we are excited to continue the development that will ultimately deliver it to patients."
Read more about Alligator Bioscience